The loss of
cancer-cell junctions and escape from the primary-tumor microenvironment are hallmarks of
metastasis. A
tight-junction protein,
Claudin 1 (CLDN1), is a
metastasis suppressor in
lung adenocarcinoma. However, as a
metastasis suppressor, the underlying molecular mechanisms of CLDN1 has not been well studied. Methods: The signaling pathway regulated by CLDN1 was analyzed by Metacore software and validated by immunoblots. The effect of the CLDN1-EPHB6-ERK-SLUG axis on the formation of
cancer stem-like cells, drug resistance and
metastasis were evaluated by sphere assay, aldefluor assay, flow cytometry, migration assay, cytotoxicity, soft
agar assay, immunoprecipitation assay and xenograft experiments. Furthermore, the methylation-specific PCR, pyrosequencing assay,
chromatin immunoprecipitation and reporter assay were used to study the epigenetic and RUNX3-mediated CLDN1 transcription. Finally, the molecular signatures of RUNX3/CLDN1/SLUG were used to evaluate the correlation with overall survival by using gene expression omnibus (GEO) data. Results: We demonstrated that CLDN1 repressed
cancer progression via a feedback loop of the CLDN1-EPHB6-ERK1/2-SLUG axis, which repressed
metastasis, drug resistance, and
cancer stemness, indicating that CLDN1 acts as a
metastasis suppressor. CLDN1 upregulated the cellular level of EPHB6 and enhanced its activation, resulting in suppression of ERK1/2 signaling. Interestingly,
DNA hypermethylation of the CLDN1 promoter abrogated SLUG-mediated suppression of CLDN1 in low-metastatic
cancer cells. In contrast, the
histone deacetylase inhibitor trichostatin A or
vorinostat facilitated CLDN1 expression in high-metastatic
cancer cells and thus increased the efficacy of
chemotherapy. Combined treatment with
cisplatin and
trichostatin A or
vorinostat had a synergistic effect on
cancer-cell death. Conclusions: This study revealed that DNA methylation maintains CLDN1 expression and then represses
lung cancer progression via the CLDN1-EPHB6-ERK1/2-SLUG axis. Because CLDN1 enhances the efficacy of
chemotherapy, CLDN1 is not only a prognostic marker but a predictive marker for
lung adenocarcinoma patients who are good candidates for
chemotherapy. Forced CLDN1 expression in low CLDN1-expressing
lung adenocarcinoma will increase the
chemotherapy response, providing a novel therapeutic strategy.